BACKGROUND: In Germany, 400 000 to 500 000 people are chronically infected with the hepatitis C virus (HCV), 70% to 80% of them with HCV genotype 1. Combined treatment with peginterferon-alfa and ribavirin leads to a sustained virologic response (SVR) in 40% to 50% of patients with genotype 1 and 70% to 80% of patients with genotypes 2 and 3. The HCV protease inhibitors boceprevir and telaprevir were approved for clinical use in Germany in 2011. METHODS: Selective literature review. RESULTS: Treatment with peginterferon and ribavirin is recommended for a variable length of time depending on the HCV genotype (24 to 72 weeks for genotype 1, 16 to 48 weeks for genotypes 2 and 3), the baseline HCV-RNA concentration (greater or less than 600 000 to 800 000 IU/mL), and the decline in HCV-RNA concentration after 4 and 12 weeks of treatment. Either boceprevir or telaprevir is given in addition to peginterferon and ribavirin. In the approval studies, these triple combinations were shown to yield higher SVR rates than dual treatment for genotype 1 (66% to 75% versus 37% to 44%). If there is a favorable early decline in HCV-RNA, the treatment can be shortened to 24 to 28 weeks in 44% to 65% of patients with genotype 1. The SVR rates in genotype 1 patients who failed previous dual therapy were 69% to 88% for prior relapsers, 52% to 59% for partial responders, and 33% for null responders. Triple combination therapy is associated with new adverse events. CONCLUSION: Individualized treatment durations are recommended for the treatment of chronic hepatitis C with peginterferon and ribavirin. Triple therapy in combination with either boceprevir or telaprevir leads to a higher rate of SVR both in previously untreated genotype 1 patients and in those who have failed prior antiviral treatment.\
BACKGROUND: In Germany, 400 000 to 500 000 people are chronically infected with the hepatitis C virus (HCV), 70% to 80% of them with HCV genotype 1. Combined treatment with peginterferon-alfa and ribavirin leads to a sustained virologic response (SVR) in 40% to 50% of patients with genotype 1 and 70% to 80% of patients with genotypes 2 and 3. The HCV protease inhibitors boceprevir and telaprevir were approved for clinical use in Germany in 2011. METHODS: Selective literature review. RESULTS: Treatment with peginterferon and ribavirin is recommended for a variable length of time depending on the HCV genotype (24 to 72 weeks for genotype 1, 16 to 48 weeks for genotypes 2 and 3), the baseline HCV-RNA concentration (greater or less than 600 000 to 800 000 IU/mL), and the decline in HCV-RNA concentration after 4 and 12 weeks of treatment. Either boceprevir or telaprevir is given in addition to peginterferon and ribavirin. In the approval studies, these triple combinations were shown to yield higher SVR rates than dual treatment for genotype 1 (66% to 75% versus 37% to 44%). If there is a favorable early decline in HCV-RNA, the treatment can be shortened to 24 to 28 weeks in 44% to 65% of patients with genotype 1. The SVR rates in genotype 1 patients who failed previous dual therapy were 69% to 88% for prior relapsers, 52% to 59% for partial responders, and 33% for null responders. Triple combination therapy is associated with new adverse events. CONCLUSION: Individualized treatment durations are recommended for the treatment of chronic hepatitis C with peginterferon and ribavirin. Triple therapy in combination with either boceprevir or telaprevir leads to a higher rate of SVR both in previously untreated genotype 1 patients and in those who have failed prior antiviral treatment.\
Authors: Vincent Soriano; Eugenia Vispo; Eva Poveda; Pablo Labarga; Luz Martin-Carbonero; Jose Vicente Fernandez-Montero; Pablo Barreiro Journal: J Antimicrob Chemother Date: 2011-06-07 Impact factor: 5.790
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Donald M Jensen; Patrick Marcellin; Bradley Freilich; Pietro Andreone; Adrian Di Bisceglie; Carlos E Brandão-Mello; K Rajender Reddy; Antonio Craxi; Antonio Olveira Martin; Gerlinde Teuber; Diethelm Messinger; James A Thommes; Andreas Tietz Journal: Ann Intern Med Date: 2009-04-21 Impact factor: 25.391
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: Bart J Veldt; E Jenny Heathcote; Heiner Wedemeyer; Juerg Reichen; W Peter Hofmann; Stefan Zeuzem; Michael P Manns; Bettina E Hansen; Solko W Schalm; Harry L A Janssen Journal: Ann Intern Med Date: 2007-11-20 Impact factor: 25.391
Authors: Stefan Zeuzem; Rolf Hultcrantz; Marc Bourliere; Tobias Goeser; Patrick Marcellin; Jose Sanchez-Tapias; Christoph Sarrazin; Joann Harvey; Clifford Brass; Janice Albrecht Journal: J Hepatol Date: 2004-06 Impact factor: 25.083
Authors: Amina A Negash; Hilario J Ramos; Nanette Crochet; Daryl T Y Lau; Brian Doehle; Neven Papic; Don A Delker; Juandy Jo; Antonio Bertoletti; Curt H Hagedorn; Michael Gale Journal: PLoS Pathog Date: 2013-04-25 Impact factor: 6.823
Authors: Wolf Peter Hofmann; Stefan Mauss; Thomas Lutz; Andreas Schober; Klaus Böker; Gero Moog; Axel Baumgarten; Heike Pfeiffer-Vornkahl; Ulrich Alshuth; Dietrich Hüppe; Heiner Wedemeyer; Michael P Manns; Eckart Schott Journal: PLoS One Date: 2015-07-31 Impact factor: 3.240